Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
BMS doubles down on neurodegenerative diseases
by Shi En Kim
July 16, 2023
| A version of this story appeared in
Volume 101, Issue 23
In quick succession, Bristol Myers Squibb has entered global licensing agreements with both Evotec and Prothena for their neurodegenerative programs. A BMS partner since 2016, Evotec will receive $40 million for the rights to its late-stage discovery programs, plus milestone and royalty payments. BMS will pay Prothena $55 million for PRX005, an anti-tau antibody for treating Alzheimer’s disease. Earlier this year, Prothena announced that PRX005 was well tolerated among participants in Phase 1 clinical studies.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X